Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Dapoxetine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 known ✓ | P31645 | 1/20 | 0.49 |
| ▸ | HTR1B | P28222 | 12/20 | 0.57 |
| ▸ | HTR1D | P28221 | 4/20 | 0.53 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.49 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.49 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.49 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.49 |
| ▸ | NR2E1 | Q9Y466 | 1/20 | 0.49 |
| ▸ | HRH1 | P35367 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Dapoxetine SCHEMBL29387056 | 1.00 | HTR1B (0.57) | HTR1BHTR1DKCNA3KMT2ACHRNB2 | |
| Dapoxetine SCHEMBL29488428 | 1.00 | HTR1B (0.57) | HTR1BHTR1DKCNA3KMT2ACHRNB2 | |
| Dapoxetine SCHEMBL30600097 | 1.00 | HTR1B (0.57) | HTR1BHTR1DKCNA3KMT2ACHRNB2 | |
| Dapoxetine SCHEMBL3672581 | 1.00 | HTR1B (0.57) | HTR1BHTR1DKCNA3KMT2ACHRNB2 | |
| Dapoxetine SCHEMBL3679561 | 1.00 | HTR1B (0.57) | HTR1BHTR1DKCNA3KMT2ACHRNB2 | |
| Dapoxetine SCHEMBL29352095 | 0.99 | HTR1B (0.56) | HTR1BHTR1DKCNA3KMT2ACHRNB2 | |
| Dapoxetine SCHEMBL119037 | 0.99 | HTR1B (0.56) | HTR1BHTR1DKCNA3KMT2ACHRNB2 | |
| Dapoxetine SCHEMBL9292059 | 0.99 | HTR1B (0.56) | HTR1BHTR1DKCNA3KMT2ACHRNB2 | |
| Dapoxetine SCHEMBL27937194 | 0.99 | HTR1B (0.56) | HTR1BHTR1DKCNA3KMT2ACHRNB2 | |
| Dapoxetine SCHEMBL27518070 | 0.99 | HTR1B (0.56) | HTR1BHTR1DKCNA3KMT2ACHRNB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 6145 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4740962-A1 | PHARMACEUTICAL COMPOSITION, FORMULATION CONTAINING PHARMACEUTICAL COMPOSITION, KIT CONTAINING PHARMACEUTICAL COMPOSITION, PREPARATION METHOD FOR PHARMACEUTICAL COMPOSITION, AND USE OF PHARMACEUTICAL COMPOSITION | Shanghai WD Pharmaceutical Co., Ltd (CN) | 2026-05-13 | — | — | EP | claimed |
| US-12624037-B2 | Method of treating agitation, aggressive behavior, and impulse control disorder | INTRA-CELLULAR THERAPIES, INC. (US) | 2026-05-12 | — | — | US | claimed |
| US-12624036-B2 | Method of treating post-traumatic stress disorder | INTRA-CELLULAR THERAPIES, INC. (US) | 2026-05-12 | — | — | US | claimed |
| US-12599554-B2 | Pharmaceutical formulations comprising tadalafil | KYDES PHARMACEUTICALS LLC (US) | 2026-04-14 | — | — | US | claimed |
| US-20260077191-A1 | COMBINATION THERAPY FOR THE TREATMENT OF DEPRESSION | FLOW NEUROSCIENCE INC (US) | 2026-03-19 | — | — | US | claimed |
| EP-4704971-A1 | GAMMA STIMULATION AND NEUROMODULATOR COMBINATION THERAPY | Cognito Therapeutics, Inc. (US) | 2026-03-11 | — | — | EP | claimed |
| US-20260034065-A1 | EXTENDED RELEASE PHARMACEUTICAL FORMULATION | DOUGLAS PHARMACEUTICALS LTD (NZ) | 2026-02-05 | — | — | US | claimed |
| US-12514883-B2 | Compositions and methods for modulating lipid and steroid metabolism | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2026-01-06 | — | — | US | claimed |
| US-12472146-B2 | Extended release pharmaceutical formulation | DOUGLAS PHARMACEUTICALS, LTD. (NZ) | 2025-11-18 | — | — | US | claimed |
| US-20250339399-A1 | SUPRAMOLECULAR SELF-ASSEMBLY SYSTEM | BEIJING CREATRON INSTITUTE OF PHARMACEUTICAL RES CO LTD (CN) | 2025-11-06 | — | — | US | claimed |
| US-20020037828-A1 | Administration of phosphodiesterase inhibitors for the treatment of premature ejaculation | VIVUS, INC. | 2002-03-28 | — | — | US | claimed |
| US-20020013343-A1 | Methods of inhibiting platelet activation with selective serotonin reuptake inhibitors | HEARTDRUG RESEARCH, L.L.C. | 2002-01-31 | — | — | US | claimed |
| WO-2001041701-A2 | THE COMBINATION OF A SEROTONIN REUPTAKE INHIBITOR AND A 5-HT2C ANTAGONIST, INVERSE AGONIST OR PARTIAL AGONIST | H. LUNDBECK A/S (DK) | 2001-06-14 | — | — | WO | claimed |
| WO-2001041766-A1 | THE COMBINATION OF A SEROTONIN REUPTAKE INHIBITOR AND IRINDALONE | H. LUNDBECK A/S (DK) | 2001-06-14 | — | — | WO | claimed |
| EP-1085879-A2 | MULTIBINDING AGENTS THAT MODULATE THE 5-HT TRANSPORTER | Advanced Medicine, Inc. (US) | 2001-03-28 | — | — | EP | claimed |
| WO-2001017521-A1 | METHODS OF USING RAPID-ONSET SELECTIVE SEROTONIN REUPTAKE INHIBITORS FOR TREATING SEXUAL DYSFUNCTION | ELI LILLY AND COMPANY (US) | 2001-03-15 | — | — | WO | claimed |
| WO-1999063932-A9 | MULTIBINDING AGENTS THAT MODULATE THE 5-HT TRANSPORTER | ADVANCED MEDICINE INC (US) | 2000-03-16 | — | — | WO | claimed |
| WO-2000006160-A1 | TREATING DEPRESSION WITH A COMBINATION OF FLUOXETINE (PROZAC), PINDOLOL (VISKEN) AND BUSPIRONE (BUSPAR) | SANOFI-SYNTHELABO (FR) | 2000-02-10 | — | — | WO | claimed |
| WO-1999063932-A2 | MULTIBINDING AGENTS THAT MODULATE THE 5-HT TRANSPORTER | ADVANCED MEDICINE, INC. (US) | 1999-12-16 | — | — | WO | claimed |
| WO-1997041878-A1 | TREATMENT OF MOOD DISORDERS WITH A GROWTH HORMONE SECRETAGOGUE | MERCK & CO., INC. (US) | 1997-11-13 | — | — | WO | claimed |